In this issue:
Concizumab for haemophilia with inhibitors
Momelotinib vs. danazol in anaemia and myelofibrosis after JAK inhibitor
Allogeneic faecal microbiota for steroid-resistant GI acute GVHD
AVID200, a TGFβ 1/3 trap, for myelofibrosis
CAR T-cells for older patients with relapsed/refractory DLBCL
5 years of pembrolizumab for relapsed/refractory classical Hodgkin lymphoma
Natalizumab plus corticosteroids for high-risk acute GVHD
Pembrolizumab after autologous SCT for allogeneic-ineligible AML
GVHD and relapse/rejection-free survival after allogeneic SCT for severe aplastic anaemia
Allogeneic SCT for myelofibrosis: prognostic indicators and role of JAK2V617F MRD
Please login below to download this issue (PDF)